Straits Times Index
3,245.97 +9.89 (+0.31%) Nikkei
27,901.01 +326.58 (+1.18%) Hang Seng
19,900.87 +450.64 (+2.32%) FTSE 100
7,468.06 -4.11 (-0.06%) BTC-USD
17,154.52 +307.26 (+1.82%) CMC Crypto 200
404.13 +9.44 (+2.39%)
Seagen Inc. (SGEN)
Pre-market:
- Business Wire
Seagen to Highlight ADCETRIS® (brentuximab vedotin) Clinical Progress at the 2022 American Society of Hematology (ASH) Annual Meeting
BOTHELL, Wash., December 01, 2022--Seagen Inc. (Nasdaq: SGEN) today announced new data for ADCETRIS® (brentuximab vedotin) will be featured at the upcoming 64th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 10-13, 2022. The abstracts, including five oral presentations, highlight updated and interim efficacy and safety clinical trial results for ADCETRIS in both early- and advanced stage settings of classical Hodgkin lymphoma (cHL), and in patients with
- Business Wire
Seagen Announces U.S. FDA Approval of New Indication for ADCETRIS® (brentuximab vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma
BOTHELL, Wash., November 10, 2022--Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS® (brentuximab vedotin) for the treatment of pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide. The approval is based on data from a phase 3 study (AHOD1331) conducted by the Children's Oncology Group (COG
- Business Wire
Seagen to Highlight New Research from its Diverse Pipeline of Targeted Cancer Therapy Candidates at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting
BOTHELL, Wash., November 10, 2022--Seagen Inc. (Nasdaq: SGEN) today announced that data from the company’s diverse pipeline of targeted cancer therapy candidates will be presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting being held November 8-12 in Boston. The presentations highlight data from multiple ongoing clinical and preclinical research studies that employ Seagen’s proprietary antibody-drug conjugate (ADC) technology, as well as other novel cancer targeting appro
